News

Targeted Oncology22h
Strategic Advances in EGFR+ NSCLC: Navigating Evolving Treatment Paths With Dato-DXd
In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...
The Pharma Letter3h
AstraZeneca reports strong gains as US growth leads the charge
AstraZeneca (LSE: AZN) posted a robust second-quarter 2025 performance, lifted by record growth in its US business and solid ...